Fixed drug eruption masquerading as herpes simplex labialis.

Recurrent herpes simplex labialis: selected therapeutic options.

Recurrent infection with herpes simplex virus 1 (HSV1), called herpes simplex labialis (HSL), is a global problem for patients with normal immune systems. An effective management program is needed for those with frequent HSL recurrences, particularly if associated morbidity and life-threatening factors are present and the patient's immune status is altered. Over the past 20 years, a variety of ...

Patrolling monocytes sensing herpes simplex virus in severe drug eruption

Drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms (DiHS/DRESS) and Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) are severe drug eruptions characterized by contrasting clinical pictures. Sequential reactivations of several herpesviruses have exclusively been demonstrated in the former. It remains to be determined, however, why the sequent...

Treatment of recurrent herpes simplex labialis with levamisole.

Because deficient immune responses may play a contributory role in recurrent herpes simplex labialis, an immunomodulating agent, levamisole, has been advocated for therapy. Forty-two patients with a high frequency of recurrent herpes simplex labialis were followed for a mean of 7.8 months (range 4 to 12) and treated for 3 days at the onset of each episode of herpes with one of three different d...

Mucosal fixed drug eruption.

Nimesulide-induced fixed drug eruption.

BACKGROUND Nimesulide is a cyclooxygenase (COX) inhibitor with a high degree of selectivity to COX-2. It is a widely used and well tolerated nonsteroidal antiinflammatory drug that also has analgesic and antipyretic properties. The most frequently reported side effects concern the gastrointestinal tract. Pruritus and skin rash are the most common cutaneous adverse reactions. There are only eigh...